Journal of the American Academy of Dermatology
Volume 59, Issue 1 , Pages 41-54, July 2008

Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: Results of two randomized, investigator-blinded, multicenter, international, controlled trials∗

  • Boni E. Elewski, MD

      Affiliations

    • Department of Dermatology, University of Alabama, Birmingham, Alabama
    • Corresponding Author InformationReprint requests: Boni E. Elewski, MD, Department of Dermatology, University of Alabama at Birmingham School of Medicine, EFH 414 1530, 3rd Avenue South, Birmingham, AL 35294-0009.
    • ,
  • Hector W. Cáceres, MD

      Affiliations

    • Instituto de Salud Especializado del Niño, Lima, Peru
    • ,
  • Liberation DeLeon, MD

      Affiliations

    • Center for Clinical Trials, LLC, Paramount, Calif
    • ,
  • Saleh El Shimy, MD

      Affiliations

    • Dermatology Department, Misr University of Science and Technology, Cairo, Egypt
    • ,
  • Judy A. Hunter, MD

      Affiliations

    • Health Care Partners Medical Group, Torrance, Calif
    • ,
  • Nicolay Korotkiy, MD

      Affiliations

    • Department of Dermatology, Russian Medical Children's Hospital, Moscow, Russia
    • ,
  • Ingrid Johnson Rachesky, MD

      Affiliations

    • The Clinical Research Center of Northwest Florida, Panama City, Florida
    • ,
  • Victoria Sanchez-Bal, MD

      Affiliations

    • private practice, Bellflower, Calif
    • ,
  • Gail Todd, MD

      Affiliations

    • Division of Dermatology, University of Cape Town, Cape Town, South Africa
    • ,
  • LindaAnn Wraith, MBA

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ
    • ,
  • Bin Cai, MD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ
    • ,
  • Amir Tavakkol, PhD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ
    • ,
  • Rajesh Bakshi, MD

      Affiliations

    • Novartis Pharma AG, Basel, Switzerland
    • ,
  • Judit Nyirady, MD, MBA

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, NJ
    • ,
  • Sheila Fallon Friedlander, MD

      Affiliations

    • Division of Pediatric Dermatology, Children's Hospital, San Diego, Calif

Accepted 13 February 2007. published online 31 March 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by Novartis Pharmaceuticals Corporation.

 Disclosures: Drs Elewski, Cáceres, DeLeon, El Shimy, Hunter, Korotkiy, Rachesky, Sanchez-Bal, Todd, and Friedlander were study investigators and received grants or other financial support from Novartis Pharmaceuticals Corporation. Drs Cai, Tavakkol, and Nyirady and Ms Wraith are employees of Novartis Pharmaceuticals Corporation, East Hanover, NJ. Dr Bakshi is an employee of Novartis Pharma AG, Basel, Switzerland. They receive salary, stock (A.T., J.N.), stock option (A.T., J.N.), and other financial benefits from the company.

 Portions of the data were presented at the Annual Congress of the European Academy of Dermatology and Venereology in Vienna, Austria, May 16-20, 2007.

 ∗A list of all study investigators and other contributors to the study may be found at the end of the article.

PII: S0190-9622(08)00252-1

doi:10.1016/j.jaad.2008.02.019

Journal of the American Academy of Dermatology
Volume 59, Issue 1 , Pages 41-54, July 2008

Article Tools

* Image Usage & Resolution